Floatz logo

Lanreotide

Endocrine Tumors

Ipsenprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Endocrine Tumors cohort.

Asset / SponsorPhaseRating
Pembrolizumab
National Cancer Institute (NCI)
Phase 2B
Eloxatin
M.D. Anderson Cancer Center
Phase 2B
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B
Irinotecan
M.D. Anderson Cancer Center
Phase 2B
Tcr Transduced T-Cells
National Cancer Institute (NCI)
Phase 2CCC

View all 17 →

Same molecule, other indications

Lanreotide is also rated in:

lymphoceleDormant
BB
Indicative ·
64 / 100
View asset →
non-functional pancreatic neuroendocrine tumorDormant
BB
Indicative ·
64 / 100
View asset →
Rectal CarcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →